The $17.3 billion deal could negatively affect drugmakers, insurers and pharmacy benefit managers, particularly CVS Health — which owns one of the largest PBMs in the nation, according to the report.
As PBM for Wellcare, CVS Health currently gets a cut of $15 billion to $20 billion of Wellcare’s annual drug spending. The Centene acquisition would be a major loss for CVS if Centene’s PBM, RxAdvance, replaces CVS.
Humana may also be negatively affected, according to Barron’s. Humana investors have been upset that the insurer didn’t aggressively seek a deal to get more involved in Medicaid. The Centene-WellCare combination has effectively removed two potential Medicaid deal partners and would create a stronger competitor for the health insurer.
Read the full report here.
More articles on payers:
Trump administration sued over New Hampshire’s Medicaid work requirements
5 must-reads on payer-provider relationships
Sutter Health, Anthem sign new contract
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
